DRI Healthcare Reports First Quarter 2026 Results

The most recent release (2026-05-14) details Q1 2026 results. Total income rose to $50.6 million from $44.0 million a year earlier. Adjusted EBITDA reached $52.8 million with a 90% margin, up from $51.7 million / 83% margin. Adjusted cash earnings per unit jumped to $0.68 from $0.43. Net loss narrowed to $984,000. The company completed a $250 million senior secured notes offering to repay credit facilities, restructured $79.7 million of preferred securities into convertible debentures, and reactivated its Normal Course Issuer Bid. Management highlighted record income, diversified funding, and balance-sheet strengthening.

Earlier, on 2026-04-29, DRI Healthcare commented on Chiesi Group’s proposed acquisition of KalVista Therapeutics – a transaction that may trigger change-of-control provisions in the Ekterly royalty agreement, potentially giving DRI Healthcare put or buy-back rights.

The Q1 2026 report shows continued strong operating momentum. Record total income and an improved margin are incrementally positive, but the market had already priced in a robust 2025 and guided mid-teens growth in Adjusted EBITDA. The annualized Q1 EBITDA of ~$211 million is well above the 2026 guidance range of $157–$162 million, yet management did not raise guidance, implying they expect the quarter’s run-rate to moderate. The reduction in Viridian milestone obligations from $300 million to $205 million is a double-edged signal: it conserves cash but also suggests clinical milestones were missed, raising latent risk around that asset.

The KalVista acquisition commentary introduces a possible game-changing catalyst, but since the outcome is uncertain and DRI Healthcare is only evaluating its rights, the immediate materiality is limited. Taken together, the earnings release is a routine confirmation of an already positive trajectory, insufficient to re-rate the stock significantly.

DRI Healthcare Trust is a pharmaceutical royalty investment company. It owns 28 royalty streams on 22 products, with a book value of $752.9 million in intangible royalty assets. Its flagship exposures include Ekterly (sebetralstat) for hereditary angioedema, acquired pre-FDA approval, and the Viridian treatments veligrotug/VRDN-003 for thyroid eye disease. The trust receives tiered royalties on worldwide/U.S. net sales, providing long-dated cash flows.